The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Open accessPublished version of a preprint
Abstract
SARS-CoV-2 variants of concern (VOC) have arisen independently at multiple locations 1,2 and may reduce the efficacy of current vaccines that target the spike glycoprotein of SARS-CoV-2 3. Here, using a live-virus neutralization assay, we compared the neutralization of a non-VOC variant with the 501Y.V2 VOC (also known as B.1.351) using plasma collected from adults who were hospitalized with COVID-19 during the two waves of infection in South Africa, the second wave of which was dominated by infections with the 501Y.V2 variant. Sequencing demonstrated that infections of plasma donors from the first wave were with viruses that did not contain the mutations associated with 501Y.V2, except for one infection that contained the E484K substitution in the receptor-binding domain. The 501Y.V2 virus variant was effectively neutralized by plasma from individuals who were infected during the second wave. The first-wave virus variant was effectively neutralized by plasma from first-wave infections. However, the 501Y.V2 variant was poorly cross-neutralized by plasma from individuals with first-wave infections; the efficacy was reduced by 15.1-fold relative to neutralization of 501Y.V2 by plasma from individuals infected in the second wave. By contrast, cross-neutralization of first-wave virus variants using plasma from individuals with second-wave infections was more effective, showing only a 2.3-fold decrease relative to neutralization of first-wave virus variants by plasma from individuals infected in the first wave. Although we tested only one plasma sample from an individual infected with a SARS-CoV-2 variant with only the E484K substitution, this plasma sample potently neutralized both variants. The observed effective neutralization of first-wave virus by plasma from individuals infected with 501Y.V2 provides preliminary evidence that vaccines based on VOC sequences could retain activity against other circulating SARS-CoV-2 lineages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, mutations in B.1.351 and P.1 variants are associated with the more pronounced loss of neutralizing capacity.15,16,22,23,25”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [25]
In the citing paper
“In addition, Beta and Delta are relatively poorly neutralized by convalescent sera obtained from unvaccinated individuals infected with non-VOC virus ( 7 – 9 , 21 ).”
From Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa (2021) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Self-citationDetection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Self-citationAntibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Self-citationEvolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
Self-citationSARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S., Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., et al. (2021) · Science · doi:10.1126/science.abh2644 · Cited by 1,461
Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353
Self-citation
Cited by
Sorted by citations
Items 601–657 of 657
Utility of Point‐of‐Care COVID‐19 Testing in an Outpatient Otolaryngology clinic
Ganesh, M., Brawley, C. C., Khanwalkar, A. R., Mycanka, J., Conley, D. B., Kern, R. C., & Tan, B. K. (2021) · OTO Open · doi:10.1177/2473974x211049328
What did we learn from the SARS-CoV-2 vaccine breakthrough infections?Preprint
Shamnath, A., Rophina, M., Jolly, B., Bhoyar, R. C., Sivasubbu, S., & Scaria, V. (2021) · doi:10.31219/osf.io/vgjwh
New variants of SARS-CoV-2, vaccine immune response and the Brazilian reality
Andrade, M. C., Gomes, L., Mendes, V. R., & Rosa, H. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00029
Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Bideau, M. L., Edouard, S., Colson, P., Chahinian, H., Raoult, D., Yahi, N., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-783298/v2
Potent Neutralizing Activity of Polyclonal Equine Antibodies against Omicron SARS-CoV-2Preprint
Luczkowiak, J., Radreau, P., Nguyen, L., Labiod, N., Lasala, F., Herbreteau, C. H., & Delgado, R. B. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.21.481341
Contractor, D., Globisch, C., Swaroop, S., & Jain, A. K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.15.484421
Clonal diversity determines persistence of SARS-CoV-2 epitope-specific T cell responsePreprint
Zornikova, K. V., Khmelevskaya, A. A., Sheetikov, S. A., Kiryukhin, D. O., Shcherbakova, O. V., Titov, A., Zvyagin, I. V., & Efimov, G. A. (2022) · medRxiv · doi:10.1101/2022.04.18.22273961
Antibody responses to AZD1222 vaccination in West AfricaPreprint
Abdullahi, A., Oladele, D. A., Kemp, S. A., James, A. B., Salako, A. O., Ige, F. A., Fink, D., Onwuamah, C. K., Osuolale, Q., Abubakar, R., et al. (2022) · medRxiv · doi:10.1101/2022.05.04.22274668
nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination
Shahid, I. (2022) · Dr Sulaiman Al Habib Medical Journal · doi:10.1007/s44229-022-00006-x
Human Vaccines & Immunotherapeutics: news
(2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1894892
Coronaviruses Research in BRICS Countries
Fielding, B. C., & Schäfer, G. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-4027-6
Fabrication and Characterization of Mxene/Cucr2o4 Semiconducting NanocompositesPreprint
Rani, M., Shafique, R., Neffati, R., Shah, A. A., Mahmood, A., & Murtaza, G. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4118401
Bailey, S. F., & Akter, M. (2022) · Springer eBooks · doi:10.1007/978-981-19-1356-3_5
Utilizing the K18-hACE2 mouse model to develop protective COVID-19 vaccines
Wong, T. Y. (2022) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.11414
Zhu, H., Wang, Z., Zhao, C., Li, C., Liu, S., Ding, J., He, C., Liu, J., Dong, B., Yang, Z., et al. (2023) · doi:10.22541/au.168355317.70344784/v1
Goc, A., Sumera, W., Rath, M., & Niedzwiecki, A. (2023) · European Journal of Microbiology and Immunology · doi:10.1556/1886.2023.00010
Sarvmeili, J. (2022) · مجله دانشگاه علوم پزشکی اراک · doi:10.32598/jams.25.3.6932.1
Omicron variant evolved: Signs, symptoms and complications
Upadhayay, P., Chaubey, K. K., & Bhardwaj, A. (2023) · AIP conference proceedings · doi:10.1063/5.0156117
Dhotre, K., Dass, D., Banerjee, A., Nema, V., & Mukherjee, A. (2023) · Current Computer - Aided Drug Design · doi:10.2174/1573409920666230825111406
Molecular and serological testing in the setting of a global pandemic
Weidmann, M. D., Malick, M. S., Saqi, A., Szabolcs, M. J., Hsiao, S. J., Fernandes, H., & Rai, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822824-1.00036-5
Kim, E. (2023) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2023.52.008186
Kuczkowska, K., Bjerkan, L., Stubsrud, E., Husbyn, H., Chellappa, S., Hauge, A., Skarshaug, R., Torgersen, M. L., Heim, J. B., Jørgensen, M. J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46223-8
Malo-Castillo, J., Jiménez-Álvarez, H., Ludeña-Meléndez, V., Castro, S. S. M., Rodríguez-Esquivel, S. E., Ishikawa-Arias, P., Terrones, C., Chavarría, L. L., Linares-Reyes, E., & Failoc‐Rojas, V. E. (2024) · Vaccines · doi:10.3390/vaccines12040400
Monajjemi, M., Shahriari, S., Mollaamin, F., & Najaflou, N. (2023) · Journal of the Chilean Chemical Society · doi:10.4067/s0717-97072023000305924
Current Progress in Genomic and Genetic Research on Human Viral Diseases
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4833-2 · Cited by 1
Evaluation of laboratory tests for COVID-19 in South Africa.
Samsunder, N. (2023) · ResearchSpace (University of KwaZulu-Natal) · doi:10.29086/10413/23146
Chang, K., Kung, Y., Fu, S., Liu, J., Wu, K., Shi, T., Luo, Y.-H., Lin, C., Chen, J., Ping, Y., et al. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106530
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Sun, L., Zhou, B., Guo, Y., Huang, Y., Tang, Z., Wu, Z., Li, Y., Zhao, L., Shan, Y., Xu, X., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-10261-y
Nightlife and low immunity drove transmission of SARS-CoV-2 gamma in Luxembourg, 2021
Pires‐Afonso, Y., Bejko, D., Ernst, C., Huberty, C., Wienecke-Baldacchino, A. K., Berger, S., Herold, M., Walczak, C., Ogorzaly, L., Vergison, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-94323-4
Janoff, E. N., Shih, M., Donskey, C. J., Belitskaya‐Lévy, I., Bräu, N., Rodriguez‐Barradas, M. C., Chan, E. R., Zimmerman, P. A., Miller, E. K., Vaughan, L. B., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70349
Stasko, N., Arwood, L., Jandick, N., Spragion, D., Roberts, R. C., Setién, M., Henson, I., Annas, A., Fulcher, M. L., Brotton, M., et al. (2025) · mSphere · doi:10.1128/msphere.00230-25
Evolutionary Insights From the COVID Pandemic: Genomic Diversity and Origins of SARS-CoV-2
Cosentino, M. A. C., Moreira, F. R. R., D’arc, M., & Santos, A. F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-15750-9.00151-8
Modeling the Mutational Effects on Biochemical Phenotypes of SARS-CoV-2 Using Molecular Fields
Wang, B., & Xi, Z. (2025) · Biomolecules · doi:10.3390/biom15111538
Levine, K. S., Blanc, R., Wang, Q., Malca, H., Sekulovich, R. E., Jin, H., Liu, S. N., Verhoeven, C., Sullivan, B. M., Smolenov, I. V., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag141.1295
Wang, H., Yang, T., Yan, Y., Yang, F., Song, X., Zhang, S., Jiang, W., Li, M., Sun, W., Li, Y., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.11.027 · Cited by 1
Coronavirus disease 2019 and the SARS-CoV-2 variants: Virological perspectives
Chakraborty, A., Das, B. S., Lahiry, S., Bhattacharya, D., & Mukherjee, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33002-5.00007-5
Coronaviruses in human pathophysiology: a brief history of the COVID-19 pandemic
Vlasov, I. N., Shadrina, M. I., & Slominsky, P. A. (2025) · Molecular Genetics Microbiology and Virology (Russian) · doi:10.17116/molgen20254304255
Müller, M. K., Volzke, J., Subin, B., Müller, S. C., Sombetzki, M., Reisinger, E. C., & Müller‐Hilke, B. (2022) · Figshare · doi:10.6084/m9.figshare.18666522
Schröder, S., Richter, A., Veith, T., Emanuel, J., Gudermann, L., Friedmann, K., Jeworowski, L. M., Mühlemann, B., Jones, T. C., Müller, M. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26637489
Mandolo, J. J., Msefula, J., Henrion, M. Y. R., Brown, C., Moyo, B., Samon, A., Moyo-Gwete, T., Makhado, Z., Ayres, F., Motlou, T. P., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17047290
Chen, X., Zhang, Y., Yang, S., Chen, Y., Qian, S., Zhang, Z., Liu, Q., 马成宝, 余为一, Feng, J., et al. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1690554
Ayres, F., Lambson, B. E., Mkhize, N. N., Makhado, Z., Mhlanga, D., Serage, R., Moore, P. L., Wibmer, C. K., & Moyo-Gwete, T. (2026) · Structure · doi:10.1016/j.str.2026.01.006
Khairallah, A., Jule, Z., Piller, A., Bernstein, M. P., Reedoy, K., Ganga, Y., Balla, S. R., Kgagudi, P., Gosnell, B. I., Karim, F., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01427-7
Self-citationOuarab, M., Rhazzar, Z., Touil, N., & Fahime, E. E. (2026) · COVID · doi:10.3390/covid6030050
Coronaviruses in Human Pathophysiology: a Brief History of the COVID-19 Pandemic
Vlasov, I. N., Shadrina, M. I., & Slominsky, P. A. (2025) · Molecular Genetics Microbiology and Virology · doi:10.3103/s0891416825700326
Epidémiologie génomique des pathogènes au Sénégal : mycobacterium tuberculosis et SARS-CoV-2
Padane, A. (2023) · theses.fr (ABES) · doi:10.70675/e6b26f76z05baz4f66z9706zbde0e41a2626
Investigation de l’épidémie de la rougeole 2017-2019 à Marseille, France
Jaafar, R. (2022) · theses.fr (ABES) · doi:10.70675/01ade9d1z58a3z410bzb1ccz08a5cdbbec26
Étude de la réponse humorale lors de l'infection par le SARS-CoV-2
Marot, S. (2023) · theses.fr (ABES) · doi:10.70675/7d41e61azd818z408dzb17cz1c0cf0738b83
Serology survey against multiple SARS-CoV-2 variants of residents in Tainan, Taiwan
Hsu, I.-L., Du, P.-X., Chou, T.-M., Cheng, C.-C., Tsai, P.-S., Shih, H.-C., Chen, S.-C., Li, C., Ho, T., & Syu, G. (2026) · Virulence · doi:10.1080/21505594.2026.2659420
Marlin, R., Centlivre, M., Bossevot, L., Gallouët, A.-S., Alexandre, M., Planas, D., Cavarelli, M., Staropoli, I., Gros, W., Surénaud, M., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106361 · Cited by 1
Peng, X., Zhang, Q., Zhou, P., Tang, L., Liang, C., Lin, H., Liu, Z., Li, B., Sun, J., & Runyu, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1907444
Codon Mutation Probability Modeling in SARS-CoV-2
Thakur, S. K., Nizam, A. A., & Robert, N. J., V (2026) · IEEE Access · doi:10.1109/access.2026.3734209
Kelvin, A. A., Oludada, O. E., Francis, M., Isho, B., Sheikh‐Mohamed, S., Nguyen, A. P., Singh, R., Swan, C. L., Darbellay, J., Rassmussen, A., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-11002954/v1
Metadata
- Authors
- Network for Genomic Surveillance in South Africa, Cele, S., COMMIT-KZN Team, Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., Karim, F., Ganga, Y., Khan, K., Bernstein, M., Balazs, A. B., Gosnell, B. I., Hanekom, W., Moosa, M.-Y. S., Lessells, R. J., de Oliveira, T., & Sigal, A.
- Affiliations
- Africa Health Research Institute (ZA)
- Hebrew University of Jerusalem (IL)
- Centre for the AIDS Programme of Research in South Africa (ZA)
- University of KwaZulu-Natal (ZA)
- Ragon Institute of MGH, MIT and Harvard (US)
- Max Planck Institute for Infection Biology (DE)
- Corresponding author
- Sigal, Alex
- ORCID
- Cele, Sandile
- Gazy, Inbal
- Jackson, Laurelle
- Hwa, Shi-Hsia
- Tegally, Houriiyah
- Lustig, Gila
- Giandhari, Jennifer
- Pillay, Sureshnee
- Wilkinson, Eduan
- Naidoo, Yeshnee
- Karim, Farina
- Ganga, Yashica
- Khan, Khadija
- Bernstein, Mallory
- Balazs, Alejandro B.
- Gosnell, Bernadett I.
- Hanekom, Willem
- Moosa, Mahomed-Yunus S.
- Lessells, Richard J.
- de Oliveira, Tulio
- Sigal, Alex
- Venue
- Nature
- Published
- 2021-03-29
- Volume
- 593
- Issue
- 7857
- Pages
- 142-146
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC9867906
- OpenAlex
- W3148277587
- Cited by
- 651
- References
- 31
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 28 · 2023: 63 · 2022: 199 · 2021: 320
- FWCI
- 48.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Griffith Research Online (submittedVersion, other-oa)
- Funders
- South African Medical Research Council
- Inyuvesi Yakwazulu-Natali
- National Health Laboratory Service
- Medical Research Council
- National Institute on Drug Abuse (DP2DA040254)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, Beta variant, convalescent plasma, neutralizing antibodies, cross-neutralization, vaccine efficacy, spike protein, receptor binding domain, COVID-19 pandemic, South Africa
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Serotherapy, Animals, Antibodies, Viral, Cell Line, Chlorocebus aethiops, Humans, Immunization, Passive, Mutation, Neutralization Tests, South Africa, Time Factors, Vero Cells, Immune Evasion, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
